Nasopharyngeal Carcinoma in Children and Adolescents: Single Institution Study
10.15264/cpho.2014.21.2.114
- Author:
Jung Yoon CHOI
1
;
Hyoung Jin KANG
;
Hee Young JU
;
Che Ry HONG
;
Il Han KIM
;
Sung Hye PARK
;
In One KIM
;
Kyung Duk PARK
;
Hee Young SHIN
Author Information
1. Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea. hyshin@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Nasopharyngeal neoplasms;
Pediatrics;
Chemoradiotherapy;
Korea
- MeSH:
Adolescent;
Bleomycin;
Carcinoma;
Carcinoma, Squamous Cell;
Chemoradiotherapy;
Child;
Cisplatin;
Diagnosis;
Disease Progression;
Drug Therapy;
Epirubicin;
Fluorouracil;
Follow-Up Studies;
Humans;
Korea;
Medical Records;
Mortality;
Nasopharyngeal Neoplasms;
Neck;
Osteosarcoma;
Pediatrics;
Radiotherapy;
Retrospective Studies;
Seoul;
Shock, Septic;
Survival Rate
- From:Clinical Pediatric Hematology-Oncology
2014;21(2):114-120
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Nasopharyngeal carcinoma (NPC) is very rare in children and adolescents. The aim of this study was to evaluate clinical characteristics and treatment outcomes of pediatric NPC.METHODS: Medical records of 9 patients treated for NPC at the Seoul National University Children's Hospital between 1988 and 2012 were analyzed retrospectively.RESULTS: The median age at diagnosis was 11 years (range, 9-13 years). One patient had stage II disease, 3 had stage III disease, and 5 had stage IV disease. The histologic subtypes were undifferentiated carcinoma and squamous cell carcinoma in 7 and 2 patients, respectively. All patients were initially treated with cisplatin (100 mg/m2 intravenous [IV] every 4 weeks for 4-6 months), bleomycin (15 unit/m2 IV every 1 weekx7), and fluorouracil (1,000 mg/m2 IV every 4 weeks for 1 year). Eight patients received radiotherapy with doses of 45-59.4 Gy at the primary site and neck nodes. Seven patients (77.8%) achieved complete remission, 1 (11.1%) achieved partial remission, and 1 (11.1%) showed disease progression. Six patients developed fluorouracil-related neurotoxicity; the regimen was changed to cisplatin, epirubicin, and bleomycin in five of the 6 patients. One patient died of progressive disease without responding to treatment. Treatment-related mortality occurred in 1 patient owing to septic shock. Secondary osteosarcoma developed in 1 patient 6 years after treatment. The overall survival was 77.8%, with a median follow-up of 40.8 months (range, 4.5-287.6 months).CONCLUSION: Children and adolescents with advanced NPC treated with combined chemotherapy and radiotherapy have a good survival rate.
